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S/M: Schwannomin / merlin protein 
Sub-occ: Sub-occipital approach 
Translab: Translabyrinthine approach 
VS: Vestibular schwannomas 
VSTR: Vestibular schwannomas tumor remnants 
  
 
15 
 
Plan 
INTRODUCTION	  ......................................................................................................................................	  16	  
METHODS	  ..................................................................................................................................................	  29	  
RESULTS	  ....................................................................................................................................................	  31	  
DISCUSSION	  ..............................................................................................................................................	  41	  
CONCLUSION	  ............................................................................................................................................	  48	  
BIBLIOGRAPHY	  .......................................................................................................................................	  49	  
TABLE	  OF	  CONTENTS	  ............................................................................................................................	  54	  
 
  
 
16 
 
 
Introduction 
 Vestibular schwannomas (VS), historically called acoustic neuromas, are 
histologically benign tumors arising from the Schwan-cells. Due to their histologically 
benign nature, the complex anatomy of the cerebello-pontine angle (CPA) and the 
morbidity and mortality related to surgery, the therapeutic management of vestibular 
schwannomas remains a major challenge. 
 
History, Epidemiology of VS 
 History 
 VS were first described by Sandifort in 1777 as a neuroma or neurilemoma.  It was 
only at the end of the 18th century, with the work of John Hunter, that the clinical 
symptomatology of these tumors began to be understood. At the end of the 19th century, 
the knowledge of the clinical presentation and evolution of the VS allowed physicians to 
make the diagnosis of VS not only during post-mortem examinations but also in live 
patients. 
 In 1895, Annandale was the first to successfully surgically remove a vestibular 
schwannoma in a 25 year-old pregnant woman, who afterwards gave birth under normal 
circumstances. 
 Epidemiology 
 VS represent 9% of brain tumors, 25% of posterior fossa tumors and are the most 
common tumor of the cerebello-pontine angle with 80% prevalence (1). 
 The incidence of VS is 2/100,000 per year, currently increasing as the initial size at 
diagnosis decreases. These changes in the epidemiology of the VS are described as a 
consequence of the multiplication of brain MR-scan investigations, leading to an increase 
of incidental radiological diagnosis without clinical symptoms (2, 3). The occurrence of 
VS is more common in women from 40 to 60 years of age. 
 VS are sporadic tumors in 95% of cases. But in 5% of cases, their occurrences are 
related to type 2 neurofibromatosis (NF2). In fact NF2 patients almost systematically 
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present an occurrence of VS. VS in NF2 patients are often bilateral, among the usual 
clinical features of neurofibroma and plexiform neuromas.  
Pathology and pathophysiology of VS 
 Pathology 
 VS are extra-axial, benign tumors arising from the Schwann cells constituting the 
myelin sheath of the VIIIth nerve. The most common site of genesis of VS is the 
Obersteiner-Redlich zone, defined as the junction of the cranial nerve between the central 
and peripheral myelination. 
 Macroscopically, VS are usually described as a unilateral lonely firm yellow / 
brown tumor without a distinct capsule. These tumors drive back the vestibular nerve 
without invading it and push on the arachnoid sheath. The persistence of a thin arachnoid 
sheath around the tumor is described and used during surgery to help the dissection of the 
tumor (Figure 1). 
 
 
Figure 1: Macroscopical aspect of VS 
a) Frontal anterior view of a VS in the right cerebello-pontine angle 
b) Closer superior view of a VS in the left cerebello-pontine angle 
 
 Microscopically, 2 different types of structure coexist: the dense fibrillar tissue 
(Antoni A) composed of compact fusiform cells, reticulin and collagen and the faint 
reticular tissue (Antoni B), made of loose stellate round cells in stroma. Also, anuclear 
palissading cells called Verocay bodies can be observed in VS tumors (Figure 2). 
 
a) 
 
b) 
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Figure 2: Microscopical aspect of VS 
Magnification x50, hematoxylin-eosin-safron staining 
A: Antoni A fibers, B: Antoni B fibers, C: Verocay bodies 
  
 Pathophysiology 
Most of the recent understanding of pathophysiological mechanisms responsible for 
the genesis and growth of VS came from the study of NF2 patients. 
 NF2 gene is located on chromosome 22q12. This gene is expressed at high levels 
during embryonic development and in an adult’s life, in the Schwann cells, the meningeal 
cells, the lens and the nerves.  
 
 This NF2 gene leads to the production of a protein called schwannomin/merlin 
(S/M). S/M is a 590 amino-acid protein, related to a family of cytoskeleton-to-membrane 
protein linkers and has been shown to interact with cell-surface proteins (Figure 3). These 
proteins are involved in cytoskeletal dynamics and in regulating ion transport as well as 
motility and growth of the Schwann cells by their interaction with CD44 and RhoGTPases. 
The NF2 gene acts as a tumor suppressor gene. Its alteration is the cornerstone of the 
Schwann cells proliferation and the genesis of VS, leading to the absence of expression, or 
the expression of a non-functional S/M protein by the Schwann cells. 
 
 In non-NF2 patients with a sporadic unilateral vestibular schwannoma, it has been 
shown that in 60% of cases a gene mutation leading to the production of a non-functional 
variant of S/M or the absence of its production is observed. In the remnant cases, it may be 
supposed that the expression of S/M is regulated by epigenetic factors and the action of 
protein cascades like caspases (4). 
 
A 
B 
C 
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Figure 3: 3D modeling of the schwannomin/merlin (5) 
 
Clinical presentation of VS 
 The clinical presentation was well described by Cushing and updated and 
summarized by Pertuiset in 1970 (1, 6). They described that typically the clinical 
presentation of VS is progressive and evolves gradually into 2 successive groups of clinical 
signs: the otological signs and then the neurological signs.  
 
 Otologic symptoms 
The otologic symptoms are the first to occur. They are characterized by a unilateral 
perception hearing loss, tinnitus and vestibular signs. 
 
 Neurologic symptoms  
 Afterwards the neurologic signs appear. They are caused by the shift and mass 
effect induced by the VS on the brainstem. Neurological signs like ataxia, gait disturbance, 
facial function impairment and hydrocephalus may be noticed. Among the neurological 
signs, the search for cranial nerve impairment is critical and conditions the therapeutic 
management of VS. For example, Vth cranial nerve impairment will be searched for with 
the corneal reflex. Its impairment is the sign of an ocular risk with an increased risk of 
keratitis. VIIth cranial nerve impairment, which is important for the post-operative facial 
prognosis and surgery, is searched for and quantified using the House-Brackmaan scale 
(7)(Table I). 
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Table I: House-Brackmann classification for facial palsy 
Grade Definition 
I Normal symmetrical function in all areas 
II 
Slight weakness noticeable only on close inspection 
Complete eye closure with minimal effort 
Slight asymmetry of smile with maximal effort 
Synkinesis barely noticeable, contracture or spasm absent 
III 
Obvious weakness, but not disfiguring 
May not be able to lift eyebrow 
Complete eye closure and strong but asymmetrical mouth movement with 
maximal effort 
Obvious, but not disfiguring synkinesis, mass movement, spasm 
IV 
Obvious disfiguring weakness 
Inability to lift brow 
Incomplete eye closure and asymmetry of mouth with maximal effort 
Severe synkinesis, mass movement, spasm 
V 
Motion barely perceptible 
Incomplete eye closure, slight movement corner mouth 
Synkinesis, contracture, spasm usually absent 
VI No movement, loss of tone, no synkinesis, contracture, or spasm 
 
 However, usually, neurological symptoms tend to no longer be observed in most 
cases. In fact patients with ontological symptoms have complementary examinations. The 
sensitivity of auditory evoked potentials and the easy and early use of the MR-scan to 
investigate any unilateral perception hearing loss has led to the radiological diagnosis of 
small intracanalar VS of few millimeters in size, without the usual constellation of signs 
described in previous publications before the MR-scan era. 
Complementary examinations  
 Audiometry 
 Both tonal and vocal audiometries are performed in the audiometric screening. A 
unilateral perception surdity associated with an early impairment of intelligibility is the 
main feature observed in VS. 
 The criteria to define and analyze this hearing loss and to guide the therapeutic 
management decision were defined in the Tokyo consensus. The Tokyo criteria use both 
the tonal and vocal audiometry to highlight the functional audition (8). The most common 
feature in tonal audiometry is an asymmetrical high-frequency sensorineural hearing loss 
(Figure 4). 
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Figure 4: Audiometric investigations for VS diagnosis 
a) Tonal audiometry in VS patient, courtesy of Prof. Timothy Hain. 
b) Classification diagram of hearing according to the Tokyo consensus meeting. 
PTA: Total auditory loss  SDS: Syllable discrimination threshold 
 
 MR-scan 
 For the radiological diagnosis and evaluation of VS, the MR-scan has replaced the 
CT-scan and has been established as the gold standard, with a sensitivity and specificity up 
to 100%. The Koos classification is the most commonly used in diagnosis and therapeutic 
management of VS (9) (Table II). 
 
 The most commonly used sequences are T1-weighted sequences with and without 
gadolinium enhancement, T2 weighted sequences with High-resolution (CISS) and T2-
FLAIR weighted sequences. The spatial resolution is sufficient with a slice thickness of 
1mm and a slice spacing of 0.8 mm allowing 3D reconstruction. 
 
 The major role of the MR-scan in the diagnosis of VS should not exempt the use of 
a CT-scan with 3D reconstruction in bone window for the pre-surgical planning. This exam 
will allow physicians to assess the pneumatization of the mastoid bone, the procidence of 
the jugular bulb, which conditions the surgical approach, and the existence of a protrusion 
of the posterior canal, useful if the audition is to be preserved. 
 
Normal 
Usable 
Useless 
Useless 
Measurable 
a) 
 
b) 
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Table II: Koos classification of VS 
 
 
Therapeutic management options 
 VS are benign tumors, which do not recur after complete removal. Their 
localization in the cerebello-pontine angle, their benign histological nature and the 
potential surgical morbidity and mortality due to the anatomical complexity of the 
cerebello-pontine angle make their treatment a technical challenge. 
 There are 3 main possibilities in management of VS: surgery, radiosurgery or a 
“wait-and-see” policy, consisting of a simple clinical follow-up with regular MR-scans. 
Grade Definition MR-scan illustration 
I Intracanalar tumor 
 
II 
Tumor spreading in the 
cerebellopontine angle without 
reaching the pons 
 
III 
Tumor touching the pons, perhaps 
deforming it but without shifting it 
 
 
IV 
Tumor deforming the pons and 
shifting the 4th ventricle 
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Decision management of VS is complex, depending on a multitude of factors influencing 
the therapeutic attitude. 
 
 Historical management of VS tumors 
 The evolution of the therapeutic management of VS follows the evolution of 
Neurosurgery. 2 main periods can be described: the Neurosurgical period and the 
Otoneurosurgical period. 
  The Neurosurgical period 
 The Neurosurgical period took place in the first 60 years of the 20th century, with 
eminent figures like Cushing, Dandy and House. At this time, the goal of the surgery was 
to save the life of a bed-ridden patient in a life threatening condition due to large VS 
compressing the brainstem. The only therapeutic option was surgery with a sub-occipital 
approach. This surgical procedure was complex and had a mortality rate of 15.4% for 
partial resection with Cushing (1) up to 30% for complete resection with Dandy (10), and 
an almost systematic post-operative ipsilateral facial palsy. 
  The Otoneurosurgical period 
The Otoneurosurgical period began at the end of the 1950s with the growing 
implication of Otologists in the diagnosis and treatment of VS. At this time, the diagnosis 
was refined and made at an early stage with a predominance of otological signs making VS 
patients “otological patients” rather than neurosurgical patients. This modification in the 
VS patient recruitment had a direct impact on the therapeutic objectives. VS surgery 
became more a functional surgery to avoid the appearance of neurological signs rather than 
a life-saving procedure, the primary therapeutic objective became the removal of the tumor 
with post-operative functional consequences. Otologists were the first to use peroperative 
microscopy (11) and they soon suggested transpetrous approaches. 
  Nowadays 
The current trend in the therapeutic management of VS is the conservation of the 
facial function after surgery, before the complete resection of the tumor. For this, new 
approaches have been developed, with 2-stage surgery or planned sub-total surgery with 
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secondary radiosurgery (12, 13). Post-surgical mortality has become rare and post-surgical 
morbidity and facial palsy have decreased with the use of these techniques. 
More recently, some surgical teams have even extended the indication of primary 
radiosurgery for large VS (14). 
 
 Surgery 
 Different surgical approaches have been described. Each technique has its 
advantages and disadvantages, and the preferential use of one technique is also dependent 
on the surgical team’s experience. 
 Whatever the surgical approach used, there are several common techniques: 
operative microscope, microsurgical instrumentation, ultrasonic vacuum and continuous 
per-operative facial nerve monitoring. 
 
 Historically, the suboccipital approach was the first described and used by Cushing 
to perform the first VS resection. This surgical approach is currently suspended due to per- 
and post-operative complications caused by the seated position of the patient and the 
absence of visualization of the intracanalar portion of the tumor making a complete 
resection impossible. 
  Translabyrinthine approach 
The translabyrinthine approach is one of the surgical approaches used nowadays. It 
was first described by Panse in 1904 and popularized by House with the publication of a 
group of 53 patients in 1964, with a sharp decrease in mortality and post-surgical facial 
palsy, with a 7% mortality rate and a normal facial function in 72% of cases in a group of 
200 patients in 1968 (15, 16). 
 It is the elective surgical approach for large VS Koos III or IV, with an ipsilateral 
cophosis (Tokyo score C or worse) because this technique requires drilling the temporal 
bone and going through the cochlea and the semi-circular canals. Also, procidence of the 
jugular gulf and pneumatization of the mastoid bone should be assessed prior to surgery, 
an important procidence or a poor mastoid pneumatization may push the physician towards 
a retrosigmoid approach (17). 
 For this technique, the patient is placed in a dorsal decibitus position. Then the 
surgeon performs a retro-auricular incision, followed by a craniotomy by drilling the 
mastoid bone and the labyrinth. For the translabyrinthine drilling, the borders of the 
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craniotomy are the middle fossa’s dura mater in cranial, 2cm after the bare sigmoid sinus 
in dorsal, the jugular gulf in caudal and the posterior face of the internal auditory canal in 
frontal. After opening the dura mater, the facial nerve is identified, the dissection of the VS 
begins with the cisternal portion with tumor volume regression allowing the physician to 
gradually continue the dissection of the VS from the facial nerve towards its apparent 
origin form the pons, and towards the internal auditory canal (18) (Figure 5). 
 The advantage of this technique is to offer a large exposure of the internal auditory 
canal and a good visualization of the facial nerve without retraction of the cerebellum, 
making this surgical approach the best option for a complete removal of the VS with 
optimal facial function preservation.  
 
 
Figure 5: Cranial nerves and tumor exposure using the translabyrinthine approach 
  Retrosigmoid approach 
 The retrosetrosigmoid approach is the second most often used surgical approach for 
VS. This is a versatile approach, well known by most neurosurgeons, allowing a wide 
access to the cerebello-pontine angle. It allows access to the internal auditory canal with a 
trajectory parallel to the petrous bone. 
 It is the elective surgical approach for large VS with serviceable hearing, whereas a 
translabyrinthine approach would normally be considered appropriate (18). 
 For the procedure, the patient is placed in the park-bench position. First, the 
surgeon locates the cutaneous projections of the transverse sinus with the horizontal line 
crossing the inion, and the sigmoid sinus with the vertical line crossing the tip of the 
mastoid. Then, an S-shaped incision crossing the projection of the transverse sinus is 
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performed, followed by a retrosigmoidian craniotomy limited at the front by the sigmoid 
sinus and at the top by the transverse sinus, with careful obturation of the mastoid air cells 
to prevent cerebrospinal fluid leakage. The dura mater is open and a retractor gently placed 
on the cerebellum (Figure 6). The posterior lip of the internal auditory canal is then drilled 
to expose the intracanalar portion of the tumor (18, 19). Afterwards, the surgeon proceeds 
with the gentle removal of the VS, as described in the translabyrinthine approach, with 
continuous monitoring of the facial nerve.  
 
 
Figure 6: Cranial nerves and tumor exposure using the retrosigmoidian approach 
 
 The advantage of the retrosigmoidian approach compared to the translabyrithine 
approach is the possibility of hearing preservation at the price of an insufficient exposure 
of the internal auditory canal, thus making the GTR more difficult. This technique is 
described by Samii as providing sufficient access to the area and offering the possibility of 
complete tumor removal in a safe way with a very low complication rate and a good 
hearing preservation rate in small VS (20). However these results are discussed concerning 
the hearing preservation rate and, to our opinion, the surgeon should favor the 
translabyrinthine approach compared to the retrosigmoidian approach, to focus on an 
optimal resection of VS. 
 
 Radiosurgery 
 The use of radiosurgery is the most recent therapeutic advance in VS management. 
This technique was developed by Lars Leksell in 1951 and tested for the first time in the 
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treatment of trigeminal neuralgia (22). The first stereotatic radiosurgical treatment of VS 
was performed in 1969 (23). 
 The goal of radiosurgery is to stop the growth of the VS and preserve cochlear and 
other cranial nerve function. The long-term benefits of radiosurgery in VS control have 
established this technique as an important minimally invasive alternative technique to 
microsurgery for Koos I-III VS (24). 
 Prior to the procedure, a sterotactic frame is attached to the head of the patient and 
a MR-scan is done with a high resolution T2-weighted sequence to show the cranial nerves 
and the internal auditory components like the cochlea. Afterwards, a multidisciplinary 
team composed of a neurosurgeon, a radiation oncologist and a medical physicist does the 
radiosurgical dose planning. This planning is critical to allow an optimal dose to be 
delivered to the VS without harming the peripheral structures. Then, after the validation of 
the radiosurgical planning, the patient is installed in the Gamma-knife and the planned 
dose is delivered. Patients are observed for a few hours and are discharged from the 
hospital in less than 24 hours (24). 
 The main advantage of this technique is its non-invasive character, with a low risk 
of complication, allowing an ambulatory management of patients. 
 However, radiosurgery is not the recommended option for therapeutic management 
for patients with large VS, especially with neurological symptoms, because of the delay 
between the radiosurgery and its effect and the risk of a transient tumor swelling after 
radiosurgery that may worsen the symtomatology. 
 Despise these known risks, recent studies tends to suggest radiosurgery even for 
large VS with an acceptable control rate and hearing preservation, at the price of an 
increased regrowth and post-surgical morbidity compared to radiosurgery in smaller VS 
(14). 
 
 “Wait-and-see” 
As VS are benign tumors with a slow progression, a late onset of clinical symptoms 
compared to the development of the tumor, and therapeutic options with potential side 
effects, the option of a simple follow-up may be discussed.  
 The goal of this attitude is to delay the therapeutic management if possible until the 
remaining days of life in the elderly, and to defer potential adverse effects of the treatment 
for as long as possible in young patients. The patient has a clinico-radiological follow-up, 
with regular clinical examination and MR-scan, every 6 months in our department. 
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 With this “wait-and-scan” policy, Konziolka describes a growth rate of 70% at 5-
years and 95% at 10-years after diagnosis (25). Huang reports a spontaneous regression 
rate of 3.8% with simple follow-up on a series of 1261 VS (26). 
 This makes a “wait-and-see” policy a viable alternative to surgery and radiation, 
especially in small VS koss I-II and the fortuitous VS discoveries on MR-scans. 
 
Therapeutic management issues of post-surgical VS remnant 
 As we saw before the previous trend in therapeutic management of VS was to treat 
surgically with a complete resection even at the price of an impairment of the facial 
function. But nowadays, facial palsy is considered as a severe handicap by the patient and 
is no longer considered as an acceptable post-operative result. This attitude has led to a 
change of approach with the preservation of the facial function as the first aim of the 
surgery, before the complete resection of the VS (27-29). 
 
 Surgeons prefer to leave a small remnant instead of risking the facial function of the 
patient by performing a complete resection, and this change of attitude in VS surgery is 
leading to an increase in the prevalence of post-operative vestibular schwannoma’s tumor 
remnants (VSTR), which makes the problematic of VS remnant’ management a more 
frequent question. 
 There is no defined therapeutic attitude towards this VS remnant. Some surgical 
teams recommend systematical radiosurgery (12, 30-34) while other teams have adopted a 
“wait-and-see” attitude (35, 36). 
Despite being safe compared to surgery, radiosurgery is not without potential side 
effects and complications especially in a post-surgical cerebello-pontine angle, and its 
place as a systematic treatment of VS post-surgical remnant is widely discussed. 
 
Objectives of the study 
 The objectives of this original study are to define the best therapeutic attitude 
towards post-surgical VS remnant tumors and to identify the factors of VS remnant 
progression. 
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Methods 
 Patient population 
 Every patient who underwent surgical treatment of VS in the Department of 
Neurosurgery of the University Hospital of Angers between 1977 and 1st May 2013 were 
included. All patients had a planned gross total resection (GTR). The surgical indication 
was the appearance of neurological symptoms or hydrocephalus. Most of the VS were 
stage III or IV on the Koos classification, and no longer had a useful hearing capacity 
before surgery, with a Tokyo score of C or worse (8, 9). The diagnostic was confirmed 
histologically in all cases. 
 
 Surgical technique 
 A multidisciplinary team, composed of a neuro-otologist and a neurosurgeon 
performed the surgical procedures. The primary surgical objective was the GTR and 
internal auditory canal decompression, with preservation of the facial function. The facial 
function was continuously checked during the intervention by facial nerve monitoring. The 
surgical procedure was halted when the facial nerve stopped responding to 
neurostimulation during surgery or when the surgeon estimated that the benefit/risk ratio 
regarding facial function preservation was weighted against the GTR of the tumor, and 
chooses to leave a small tumor remnant to avoid any facial nerve lesions. 
 
 Clinico-radiological follow-up 
 All patients benefited from a multidisciplinary follow-up by their neuro-otologist 
and neurosurgeon with regular consultations and control MR-scans. 
 The first MR-scan and first consultation were performed 3 months after surgery. 
Therapeutic attitude towards the VS remnant was then decided on depending on the size of 
the residual tumor and the age of the patient. 
 Follow-up was then at six months and then yearly after the first post-op 
consultation with clinical and MR-scan surveillance. 
 
 MR-scans were carried out with a 1.5 T Siemens Magnetom MR-scan. The chosen 
sequences were T1-weighted with and without gadolinium enhancement, T2 High-
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resolution (CISS) and T2-FLAIR weighted, each with a slice thickness of 1mm and a slice 
spacing of 0.8 mm allowing for 3D reconstruction. 
 
 Data collection and Analysis 
 We did a retrospective study on patients treated or followed up for a VS in the 
Department of Neurosurgery of the University Hospital of Angers since its opening in 
1977. The primary end-point for data collection and survival analysis was fixed at the 1st 
May of 2013. 
 
 All the files of patients treated surgically with a planned GTR and with a per-
operative tumor remnant described by the surgeon were collected and analyzed. Patients 
with a per-operative tumor remnant and a “wait-and-see” therapeutic management of the 
VSTR were included for statistical analysis. 
 
 The following datas were collected: -­‐ Age at diagnosis -­‐ The initial VS size (in cm3) -­‐ Koos stage -­‐ Existence of a cystic component  -­‐ Existence of a type 2 neurofibromatosis (NF2) -­‐ Surgical access -­‐ Per-operative tumor remnant size, estimated by the surgeon -­‐ VSTR location -­‐ VSTR size at each consultation during follow-up (in cm3) -­‐ Follow-up duration in months and the reason and the secondary therapeutic decision 
made. -­‐ Facial nerve function before, after surgery and at the primary end-point using the 
House-Brackmann classification (7) 
  
 The volume of the VS initial size and the VS remnant size was calculated for each 
MR-scan using a contrast enhanced T1-weighted sequence with a slice thickness of 1mm 
and slice-spacing of 0.8 mm allowing for 3D reconstruction. The 3-plane tumor radii were 
measured on DICOM images using a multiplanar reconstruction mode (37). 
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 Statistical analysis was then undertaken with two-sample T-tests, or ANOVA 
followed by a post-hoc test, for the descriptive and comparative analysis of the different 
subpopulations. A Cox-model and Kaplan-Meier survival analysis were undertaken in the 
search for the remnant’s recurrence factors with remnant progression defined as the main 
event. 
 
 The regression of the VSTR was defined by the reduction by at least 25% of the VS 
volume between two successive MR-scans whereas progression was defined by an increase 
of at least 10% in volume. 
 
 The most appropriate timing of the post-surgical MR-scan checkup being subject to 
discussion (38), datas were analyzed and VSTR evolution assessed with a MR-scan 
reference done 3 months or 1 year after surgery. 
 
Results 
Description of the population in the study 
 Among the 600 patients followed in our Department of Neurosurgery for VS, 256 
underwent surgery and 65 patients presented a per-operative VSTR described by the 
surgeon, meaning a GTR rate of 74.6% (Figure 7).  
 In this population of 65 patients, 17 patients with a VSTR observed per-operatively 
by the surgeon didn’t have a radiologically confirmed GTR. This gives a concordance rate 
of 74% between the surgeon’s appreciation and the MR-scan check with an overestimation 
of the presence of a VSTR by the surgeon. In addition, 1 patient died of meningitis before 
the first checkup MR-scan and 1 patient dropped out of the study due to a transfer to 
another University hospital to be closer to his home for post-operative surveillance and 
follow-up.  
 Among the 46 remaining patients with a per-operative VSTR confirmed on the first 
checkup MR-scan, three sub-populations with different therapeutic management 
approaches were defined: 2 young patients had a planned 2-staged GTR and underwent a 
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second surgical intervention just after the first checkup MR-scan, 4 young patients with a 
large VS remnant were referred immediately to radiosurgery and 33 patients underwent a 
simple follow-up. We excluded 7 patients who had recently undergone surgery and hadn’t 
had a checkup MR-scan after the beginning of the clinico-radiological follow-up to allow 
the radiological assessment of VSTR evolution (Figure 5, Table III). 
 Therefore we included in our study the 33 patients who had a per-operative VSTR 
confirmed on the first MR-scan and underwent a simple follow-up. 
 
 
 
Figure 7: Flow-chart of the population of VS patients followed at the University 
Hospital of Angers 
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Table III: Characteristics of the population 
 
 Population n= 33 
Age at diagnosis (year) 52,4 ± 15,1 
Initial volume before surgery (cm3) 9,8 ± 6,4 
Koos stage 
  - III 
  - IV 
  
11 (33 %) 
22 (67 %) 
Cystic component 8 (24 %) 
NF2 3 (9,1 %) 
Surgical access 
  - Translabyrinthine 
  - Retrosigmoidian 
  - Sub-occipital 
  
28 (85 %) 
3 (9 %) 
2 (6 %) 
VSTR location 
  - CPA 
  - IAC 
  - Porus 
  
19 ( 58 %) 
5 (15 %) 
9 (27 %) 
VSTR size at first checkup MR-scan 0,75 ± 2,36 
Follow-up duration (months) 60 ± 65,3 
Pre-operative facial function 1 ± 0,2 
Post-operative facial function 2,53 ± 2 
Facial function at end-point date 2 ± 1,66 
 
Evolution of the “wait-and-see” population 
 Among patients with VS, we must distinguish patients with NF2. Indeed, their 
different pathophysiological features make them stand out from the non-NF2 population by 
their clinical evolution, the number of lesions, their evolution and the different histology 
(39-41). So, to refine our analysis and to differentiate the potential therapeutic management 
approaches between NF2 and non-NF2 patients, we decided to continue our analysis only 
with non-NF2 patients. The evolution of the NF2 patients will be discussed in a separate 
paragraph. 
 
 “Wait-and-see” non-NF2 patients with reference MR-scan 3 months 
after surgery 
 In this population of 30 non-NF2 patients, three months after surgery, we observed 
a progression of the VSTR in 7% of the population, 50% with tumor remnant stability and 
43% with spontaneous regression (Figure 8). 
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 The average follow-up duration was 45 months for the patients with a spontaneous 
VSTR regression, 57 months for the stable group and 48 months for the progression group 
(Table IV). No statistical difference was shown between the different durations of follow-
up (p=0,84). 
 
 Univariate analysis showed a significant association between an impaired facial 
function after surgery and the progression of the post-surgical VSTR in non-NF2 patients 
(p= 0,02 in univariate analysis). We also observed a strong association between large VS 
before surgery and a large VSTR with the risk of recurrence (both p= 0,06)(Table IV). 
 In multivariate analysis, the VS remnant size is significantly higher in the 
progression group versus the stable group (p=0,039). Despite this interesting result, there 
isn’t a statistical association between VS remnant size and progression (p=0,097 in 
multivariate analysis). 
 
Table IV: Univariate analysis and description of the evolution of VS TR in the non-
NF2 “wait-and-see” population 
 
 Regression n=13 
Stability 
n=15 
Progression 
n=2 p value 
Age at diagnosis (year) 55,3 ± 12,3 48,9 ± 17,9 62 ± 22,6 0,64 
Initial volume before surgery 
(cm3) 7,4 ± 7,2 11 ± 6 14 ± 1,8 0,06 
Koos stage 
  - III 
  - IV 
  
5 (38 %) 
8 (62 %) 
  
6 (40 %) 
9 (60 %) 
  
- 
2 (100 %) 
0,67 
  
  
Cystic component 3 (23 %) 3 (20 %) 1 (50 %) 0,67 
Surgical access 
  - Translabyrinthine 
  - Retrosigmoidian 
  - Sub-occipital 
  
12 (92 %) 
1 (8 %) 
- 
  
13 (87 %) 
1 (6,5 %) 
1 (6,5 %) 
  
2 (100 %) 
- 
- 
0,59 
  
  
 
VSTR location 
  - CPA 
  - IAC 
  - Porus 
  
5 (38 %) 
4 (31 %) 
4 (31 %) 
  
11 (73 %) 
1 (7 %) 
3 (20 %) 
  
1 (50 %) 
- 
1 (50 %) 
0,17 
  
  
 
VSTR size at first checkup MR-
scan 1,1 ± 3,1 0,1 ± 0,2 14 ± 1,8 0,06 
Follow-up duration (months) 44,6 ± 26,7 56,6 ± 67,8 48 ± 14,1 0,84 
Pre-operative facial function 1 ± 0 1,1 ± 0,3 1 ± 0 0,16 
Post-operative facial function 2,7 ± 2,2 1,9 ± 1,6 5,5 ± 0,7 0,02 
Facial function at end-point date 1,9 ± 1,9 1,7 ± 1,3 4 ± 2,8 0,47 
 
  
 
35 
 
Figure 8: Description of the population of VS non-NF2 patients with a per-operative 
VSTR described by the surgeon. First checkup MR-scan 3 months after surgery 
 
 “Wait-and-see” non-NF2 patients with a reference MR-scan one year 
after surgery 
 The delay between surgery and the first post-operative MR-scan is subject to 
debate, usually done 3 to 12 months post-op. The main risk with an early post-operative 
MR-scan is the confusion with a post-operative tumor remnant and post-operative scar 
tissue, leading to a false underestimation of the GTR rate. To minimize this risk, we 
analyzed the population and the evolution of VS post-surgical remnant using the 1-year 
post-op MR-scan as a reference. 
 
 16 patients were included in this population. Compared to the population of NF2 
patients with a first MR-scan 3 months after surgery, 9 patients had an insufficient follow-
up duration and thus were excluded. Also, 5 patients were excluded and considered as 
GTR because of the complete regression of their VSTR remnant between the 3 months 
post-op MR-scan and the 1-year MR-scan. 
 
  In this population, we observed a progression of VSTR in 12.5% of the population, 
62.5% with stability and 25% with spontaneous regression (Figure 9). The average follow-
up duration was 43 months for the patients with a spontaneous VSTR regression, 65 
months for the stable group and 37 months for the progression group (Table V). 
 In this group too, there is a significant association between post-surgical facial 
function and the VSTR’s evolution in univariate analysis, confirmed in the multivariate 
analysis (p= 0,01 and p= 0,05) (Table V). 
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Figure 9: Description of the population of VS non-NF2 patients with a per-operative 
VSTR described by the surgeon. First checkup MR-scan 1 year after surgery 
 
Table V: Univariate analysis and description evolution of VS TR in the non-NF2 
“wait-and-see” population with first MR-scan at one year after surgery 
 
 Regression n=4 
Stability 
n=10 
Progression 
n=2 
p value 
Age at diagnosis (year) 59,8 ± 3 47,3 ± 13,8 62 ± 22,6 0,61 
Initial volume before surgery (cm3) 9,6 ± 12,9 10,4 ± 5,5 14 ± 1,8 0,14 
Koos stage 
  - III 
  - IV 
  
2 (50 %) 
2 (50 %) 
  
5 (50 %) 
5 (50 %) 
  
- 
2 (100 %) 
0,21 
  
  
Cystic component 2 (50 %) 1 (10 %) 1 (50 %) 0,67 
Surgical access 
  - Translabyrinthine 
  - Retrosigmoidian 
  - Sub-occipital 
  
4 (100 %) 
- 
- 
  
8 (80 %) 
1 (10 %) 
1 (10 %) 
  
2 (100 %) 
- 
- 
0,64 
  
  
 
VSTR location 
  - CPA 
  - IAC 
  - Porus 
  
1 (25 %) 
2 (50 %) 
1 (25 %) 
  
8 (80 %) 
- 
2 (20 %) 
  
1 (50 %) 
- 
1 (50 %) 
0,50 
  
  
 
VSTR size at first checkup MR-
scan 3,1 ± 5,6 0,1 ± 0,2 4 ± 5,6 0,59 
Follow-up duration (months) 38 ± 20 65,6 ± 75,3 31 ± 7,1 0,16 
Pre-operative facial function 1 ± 0 1,2 ± 0,4 1 ± 0 0,16 
Post-operative facial function 3 ± 2,5 1,8 ± 1,4 5,5 ± 0,7 0,01 
Facial function at end-point date 2,5 ± 2,3 1,8 ± 1,4 4 ± 2,8 0,50 
 
 NF2 patients 
 In this study, 3 NF2 patients were included, representing 9.1% of the population 
with a post-operative tumor remnant described on the first MR-scan. 
 Among the NF2 population, 2 out of 3 patients presented a VS remnant 
progression, corresponding to a 66% progression rate, with one late progression observed 
25 years after the first surgery. With these 2 VSTR progressions, NF2 patients represent 
half of the VSTR progression in the whole population of patients, despite the low 
prevalence of NF2 in the population. 
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 Due to the small number of NF2 patients included, no statistical difference was 
shown between the NF2 and non-NF2 population and no risk factor of VSTR progression 
has been identified. 
  
Survival analysis of VS remnant growth 
 Non-NF2 population 
  Overall survival curve 
 In the whole non-NF2 population, the average follow-up duration was 51 months. 
All VS remnant progression occurred between 38 and 58 months after surgery (Figure 10). 
 
 
Figure 10: Survival curve for non-NF2 patients with VS remnant 
x-axis: time in months after surgery, y-axis: probability of non-progression 
 
  Statistical analysis 
 Univariate analysis showed a significant risk of progression in patients with an 
initial tumor remnant volume ≥ 1.5cm3 or a post-operative function score ≥ 4 on the 
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House-Brackmann scale (p=0,048 and p=0,031) (Figure 11). Neither the initial tumor 
volume, nor the existence of a cystic component, the Koos stage, the surgical approach, the 
initial VSTR size or location, or the pre-operative facial function were found to be a 
prognostic factor of recurrence. 
 Multivariate analysis did not show any significant difference because of the small 
number of patients in the population. 
 However, despite a lack of significance, we observed that all remnant progression 
occurred in Koos IV patients (p= 0,6) and no recurrences of remnants located in the 
internal auditory canal were observed (p= 0,82). 
 
 
 
Figure 11: Kaplan-Meier stratification of VSTR non-progression survival curves 
x-axis: time in months after surgery, y-axis: probability of non-progression, notches and circles: censored 
data 
a) VS remnant volume with cut-off ≥ 1,5cm3 
b) Postoperative facial function with cut-off ≥ 4 
 
  Comparison with non-NF2 population, first MR-scan 1 year post-op 
 In this population, the two significant VSTR main progressions occurred at 26 and 
46 months after surgery (Figure 12). 
 
a) 
 
b) 
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 Univariate analysis showed, as in the non-NF2 group, a significantly increased risk 
of tumor remnant progression in patients with a postoperative function score ≥4 (p= 0,021) 
(Figure 10). 
 However, in this group, the presence before surgery of  VIIth nerve impairment with 
a score ≥ 2 is associated with a significant risk of progression (p= 0,001) (Figure 12). The 
initial VSTR size wasn’t identified as a progression factor in this group (p= 0,193). 
 
 
Figure 12: Survival curves for non-NF2 patients with VSTR and first MR-scan one 
year post-op 
x-axis: time in months after surgery, y-axis: probability of non-progression 
a) Overall survival curve 
b) Post-operative function with cut-off ≥ 4 
c) Pre-operative facial function with cut-off ≥ 2 
a) 
 
b) 
 
c) 
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 NF2 population 
 2 NF2 patients presented a VSTR, one at 48 months and one at 300 months (25 
years) after surgery (Figure 13). 
 Due to the small number of NF2 patients included, survival analysis was not done 
on this population because of the predictable lack of significance. 
 
 However, in the survival analysis of the whole population, the existence of an NF2 
was not found to be a significant risk factor of progression (p= 0,5). 
 
Figure 13: Survival curves for VSTR non-progression in the whole population, 
stratified by the presence of an NF2 
x-axis: time in months after surgery, y-axis: probability of non-progression, notches and circles: censored 
datas 
 
NF2 + 
NF2 - 
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Discussion 
 The therapeutic management of post-surgical VS remnants is a crucial debate in an 
era where the preservation of the facial function at all costs leads to an increase in their 
prevalence. 
 
 The management of post-surgical VS requires physicians to identify predictive 
factors of progression and to characterize the different sub-populations. The aim is to 
choose the best therapeutic attitude for each patient with the most appropriate benefit/risk 
ratio, its particularities and its individuality among the VS patient population. 
 
  Our study is, to our knowledge, the first one to focus on the natural history of VS 
post-surgical remnants and to bring out the predictive factors of progression. Our original 
study might shed new light on the best therapeutic attitude towards post-surgical VS 
remnants. We suggest following up the results with a post-surgical VS remnant assessment 
that may help to select patients at a high risk of progression. 
 
 The main limitation of this study is its retrospective analysis, posing the problem of 
non-homogenous follow-up, missing data and patients lost from the study. VS prevalence 
is low among the general population, making a prospective study long and difficult to 
undertake to reach the statistical level required to demonstrate the existence of predictive 
factors in VSTR progression between multiple variables. 
 This study also presents a selection bias, with 2-stage surgery chosen by the 
surgeons for younger people and systematic radiosurgery for young people with big post-
surgical VSTR. These strategies were chosen by the surgeons to minimize the recurrence 
rate, data about VSTR progression rate and natural evolution under surveillance not being 
available at this time. 
 However, this study doesn’t present an attrition bias, nor an evaluation bias. All 
patients, even those lost from the study, were included in this study and the same surgeon 
performed a systematic evaluation at regular time intervals. 
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Timing of the radiological assessment after VS surgery 
 The most appropriate timing for an MR-scan assessment of the existence of VSTR 
after surgery is subject to question between early and delayed post-surgical checkups.  
 The risk of an early MR-scan checkup is to confuse VSTR with post-surgical 
scaring because of the same gadolinium enhancement pattern. This distinction is critical 
for our study because of the spontaneous regression of the post-surgical scar, which can be 
confused with the spontaneous regression of a VSTR. 
 
 In our study, all VSTR patients included had the presence of a VSTR both 
confirmed per-operatively by the surgeon and described in the surgical report, and on the 
first MR-scan 3 months after surgery. This double confirmation makes the confusion of 
post-surgical scaring for spontaneous VSTR regression in our study unlikely. 
 
 Despite its interest in reducing the risk of confusion between post-surgical scaring 
and VSTR, the disadvantage of the use of a 1-year post-op MR-scan after surgery is a loss 
of information about early VSTR evolution. In our study, 5 patients with VSTR presented 
a complete spontaneous regression of their tumor remnant during the first year. This data 
would have been ignored and would have led to a false increase of the GTR of VS and a 
lowering of the VSTR spontaneous regression rate, if only the data based on the 1-year 
post surgical MR-scan had been considered. 
 
 In our opinion, the 3-month post-op MR-scan should be given priority for VSTR 
confirmation and the follow-up should be given priority for the per-operative and 
radiological confirmation of the existence of a VSTR making the risk of a false positive 
unlikely. 
 
Comparison of VS remnant evolution and progression rate with 
the literature 
 In non-NF2 patients with the first MR-scan 3 months post-op, the progression rate 
was 7%. This result is inferior to the 10% recurrence rate found in a recent study, which 
excluded NF2 patients and treated all post-surgical VS remnants with radiosurgery (12). 
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 Considering the non-NF2 population, its seems more appropriate to adopt a “wait-
and-see” attitude instead of a systematic radiosurgical treatment of VS surgical remnant, 
the benefit/risk balance being clearly in favor of a simple follow-up. 
 
 With 1 year post-op MR-scan as reference, only 22 patients had sufficient follow-
up to be included, making this population less representative and the statistical significance 
poorer. 
 In this case, we found a progression rate of 12%, equivalent to the overall 
population characteristics and similar to previous rates found in the literature. We think 
that the shrinking of the population may be the principal explanation for the increase of the 
progression percentage. 
 
 In our opinion, the therapeutic management of post-surgical VS in non-NF2 
patients should be a “wait-and-see” policy, the progression rate being equivalent or lower 
than in patients treated systematically with radiosurgery. Due to their high progression rate, 
post-surgical VS remnants in NF2 patients should be treated with radiosurgery. 
 
 Our population of NF2, despite its small size, accounts for half of the VSTR 
progression observed and has a 66% progression rate. The usual progression rate of VSTR 
for VS patients is 14.6%, higher than the usual progression rate found in the general 
population of NF2 patients (12, 31, 40, 42, 43). In the literature, NF2 patients are a specific 
entity among VS patients, with a specific medical history and specific management, 
hearing preservation being in their case the main objective due to the high prevalence of 
bilateral localizations. 
 Thus, despite the lack of scientific evidence found in the literature, it would seem 
logical to give preference to systematic radiosurgical treatment for VTSR in NF2 patients 
to minimize the progression risk and preserve the hearing for as long as possible. 
 
Predictive factors of VS remnant growth 
 This original study is the first, to our knowledge, to study the natural history of VS 
post-surgical remnants, to define the best therapeutic attitude and the factors of VSTR 
progression with the characterization of sub-populations at a high risk of recurrence. After 
demonstrating that radiosurgery should be given priority in the NF2 population and a 
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“wait-and-see” policy for non-NF2 patients, we decided to continue our investigation and 
try to bring out predictive factors for recurrence. 
 
 In the whole population, we observed that almost all VS remnant progression 
occurred 3 to 5 years after surgery, except for one NF2 patient who presented a progression 
25 years after surgery. This data is coherent with the literature (36, 44). 
 
 In each population the immediate post-operative facial function impairment ≥4 on 
the House-Brackmann grading scale was a significant progression factor. This may be 
explained by the fact that an altered per-operative facial function may lead the surgeon to 
end the intervention prematurely. This means leaving an unplanned VS remnant in size and 
location, with an unsatisfactory surgery in the surgeon’s opinion. 
 In non-NF2 patients, the initial VS remnant volume also appears to be a statistically 
significant progression predictor, with a cut-off at 1.5 cm3, inferior to the 2.5cm3 cut-off 
previously described by Vakilian (45). This predictive factor may be explained by the less 
efficient devascularization of large tumor remnants.  
 All recurring VS remnant were primary grade IV on the Koos classification, 
suggesting a potential statistical association between the initial size of the VS and the risk 
of recurrence. But the Koos stage and thus the initial volume of the VS weren’t found to be 
a statistically significant predictive factor, as described in previous studies (29, 46, 47). 
 
 The NF2 didn’t appear to be a significant tumor remnant progression factor with a 
p=0.5, despite the fact that 2 out of 3 patients presented a VS progression. However, 
despite the lack of significance which may be explained by the low prevalence of NF2 
patients in the population and the low number of NF2 patients included in this study, we 
think that NF2 is a significant risk factor for progression and that NF2 and non-NF2 
patients are 2 distinct populations with different pathological findings, clinical 
presentations, history and outcomes (41, 48). 
 NF2 patients need specific management of their VS with hearing preservation being 
the first goal of therapeutic management (39, 40). Systematic radiosurgery should be given 
priority in these patients due to a high tumor remnant progression rate, and the limited side 
effects in a population were hearing preservation is crucial. 
 Also, no significant progression was found with VS remnants located in the IAC, 
being consistent with the literature, where no progression of VS located in the IAC was 
observed (36, 49). 
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 Due to lack of statistical significance, the initial VS remnant volume was not found 
to be a predictive factor of progression in the population with the first MR-scan at one year 
after surgery. Instead, we found a significantly increasing risk of recurrence with the 
alteration of pre-operative facial function even with a small impairment (House-
Brackmann score ≥2), which can be interpreted more as a statistical association than a 
cause-effect link in this population.  
 
 In conclusion, NF2 patients have a different evolution to non-NF2 patients and 
show a higher rate of progression. 
 Post-operative facial function impairment and the initial VS remnant volume are 
found to be significant predictive factors of progression in the non-NF2 population. 
  
 We observed also that all growing VS remnants were initially Koos grade IV and 
no VS remnant progression was observed on VS remnants located in the internal auditory 
canal, but these results weren’t statistically significant. 
 
Post surgical VS remnants: therapeutic management proposal 
 Three therapeutic options are available for the management of post-surgical VS 
remnants: a “wait-and-see” attitude, radiosurgery and surgery. 
 
 A “wait-and-see” attitude is based on a regular clinico-radiological follow-up. The 
goal is to avoid systematical radiosurgical treatment of VS remnants and to keep it only for 
the few remnants that will progress over time in the population presenting a low 
progression rate. The inconvenient of this therapeutic management is the delay in treating 
the progression and the increased difficulty of treating an important remnant tumor instead 
of a small post-operative remnant. 
 
 Radiosurgery is considered as an efficient technique providing at low risk a 
minimally invasive treatment for primary VS management (32, 50-55). But, for post-
surgical VS remnants, its indications remain unclear. However, even if it is a minimally 
invasive treatment, radiosurgery may have side effects and complications like VIIth and 
VIIIth nerve lesions (46, 56). In clinical practice, radiosurgery in treatment of VS remnants 
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is acceptable only if its benefits surpass its potential risks compared to other therapeutic 
options. 
 
 Reoperation is considered less often, due to its technicality, with an important risk 
of complications higher than the two previous therapeutic options, with cranial nerve 
impairment and cerebro-spinal fluid leakage. Ramina and al. reported in their study of 
reoperation of VS that 7% of cases had facial nerve lesions, 13% had transient bulbar nerve 
palsy and 20% had cerebro-spinal fluid leakage in a group of 15 patients (57). 
 
 We suggest for patients with radiologically confirmed VS remnants a therapeutic 
management depending on the criteria highlighted in this study (Figure 13). 
 MR-scans remain the radiological exam of choice to check the evolution of post-
surgical tumor remnants, with T1 with and without gadolinium enhancement, T2 High-
resolution and T2-FLAIR weighted, each in 3D acquisitions. The poor correlation between 
the surgeon and the MR-scan checks, to determine the existence of a post-operative 
remnant, make the first checkup MR-scan the best check with a sensitivity and a specificity 
up to 100% (58). 
 The first MR-scan 1 year after surgery may allow us to minimize the risk of 
confusing a post-surgical scar for a VS remnant despite losing information about the early 
regression of post-surgical VS remnants. However, we chose to do the first MR-scan 3 
month after surgery to allow early detection of post-surgical complications, and appreciate 
early VS remnant regression, as did Roche et al. (34). 
 
 For NF2 patients presenting a high progression rate and needing special 
management to preserve both hearing and facial functions, we suggest using 
complementary radiosurgery on the VS remnant. 
 In the non-NF2 population, patients with an impaired facial function with a score 
≥4 on the House and Brackmann grading scale and patients with a VS remnant size 
≥1.5cm3 had a statistically increased risk of progression. Therefore, we suggest for these 
sub-populations of non-NF2 patients at risk of progression a complementary radiosurgical 
treatment. 
 For patients with a VS remnant, all progression occurred between 3 and 5 years 
after the first surgery. This suggests that a close follow-up during the first 6 years after 
surgery is needed, and can be more widely spaced after this critical period of surveillance 
(Figure 14). 
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 In our therapeutic management proposal, we suggest treating non-NF2 patients with 
an impaired post-operative facial function with radiosurgery. This choice of treating 
patients with an already impaired facial function with radiosurgery may be questionable 
because of the risk of aggravation. But in our study, because of a statistically significant 
risk of VS remnant growth in this population, we considered the benefit/risk ratio in favor 
of the radiosurgery treatment. 
 
 
Figure 14: Therapeutic management proposal for VS post-surgical remnant 
 
 
Spontaneous remnant regression: myth or reality? 
 The existence of spontaneous regression of post-surgical VS remnants is subject to 
question. Only a few studies report its existence and its radiological behavior (35, 59). It is 
often attributed to a post-surgical scar. 
 
 In our study, apparently spontaneous regression of post-operative remnants 
occurred in 39% of the overall population and 43 % in the non-NF2 population with a first 
MR-scan 3 months after surgery. 
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 The regression of the post-operative remnant seems to occur shortly after surgery. 
In our study, spontaneous regression of VS remnants happened in the first year after 
surgery in 60% of cases. This means that an important part of this population is excluded 
in the one-year post-op analysis and in studies based on 1-year post-surgery MR-scans. 
  
 Distinctions between a VS remnant and a post-surgical scar can be confusing. 
However, each VS remnant included in our study was described per-operatively by the 
surgeon and the tumor remnant location on first checkup MR-scan matched to the remnant 
described by the surgeon. This tends to go against the hypothesis of a post-surgical scar 
and false detection of VS remnants. 
  
 The mechanisms of the VS remnant regression remain unclear. One main 
explanation may be the devascularization of the remnant tumor during surgery, as 
described by Hahn (35). 
 
 
Conclusion 
 NF2 patients presented a high progression rate. 
 
 Initial VS remnant size ≥ 1.5 cm3 and immediate post-operative facial function 
impairment with House-Brackmann score ≥ 4 are statistically associated with a significant 
risk of VS remnant progression in non-NF2 patients. 
 
 In our opinion, the best therapeutic management of VS post-surgical remnants in 
non-NF2 patients with no predictive factor of progression is a simple clinico-radiological 
follow-up whereas, patients with a least one of the predictive factors of progression may 
benefit from radiosurgery. 
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